Recent Updates
Recently added Catalysts
ONC Positive Sentiment

BeOne Medicines Announces Third Quarter 2026 Financial Results and Business Updates

Thursday, November 5, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: BeOne Medicines Ltd. reported strong financial results for Q3 2026, showcasing significant growth in the oncology sector. The company raised its full-year guidance, reflecting its leadership in hematology, particularly with the success of its BTK inhibitor, BRUKINSA. CEO John V. Oyler highlighted the sustained response driven by this product.

Market Sentiment Analysis

POSITIVE FACTORS

  • Strong third quarter results reported.
  • Raised full-year guidance indicates growth.
  • Leadership in hematology with BTK inhibitor BRUKINSA.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+45%
120-day peak, hindsight
Typical move
2.8%
average across 15 past catalysts
Lead asset
BGB-43395
Phase 1 · Advanced Solid Tumor

Full Press Release Details

SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates from the third quarter of 2026. John V. Oyler, Co-Founder, Chairman, and CEO, BeOne, said: “Our strong third quarter results and raised full-year guidance reflect continued rapid global growth and leadership in hematology, anchored by our foundational BTK inhibitor BRUKINSA, which drives powerful and sustained respo

Frequently Asked Questions

What were BeOne Medicines' Q3 2026 results?

BeOne Medicines reported strong financial results for Q3 2026.

What did BeOne Medicines raise for the full year?

The company raised its full-year guidance following Q3 results.

What product drives BeOne's growth?

The BTK inhibitor BRUKINSA is a key driver of BeOne's growth.

Who is the CEO of BeOne Medicines?

John V. Oyler is the Co-Founder and CEO of BeOne Medicines.

ShareAdd on Google
Tags: ONC BeOne Medicines BRUKINSA oncology financial results Q3 2026
Last updated: Nov 5, 2026

Biotech snapshot

Cash runway
$5098M liquidity · $0M/mo burn
Low dilution risk
Lead asset
BGB-43395Phase 1
Advanced Solid Tumor →

Catalyst track record

+45%
best trade around ONC's most recent catalyst

Peak hindsight return over a 120-day window, across 15 tracked FDA/PDUFA catalysts for ONC.

See every catalyst's timing & PoA →